These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 1177632)

  • 1. [L-dopa + peripheral decarboxylase antagonist].
    Wiesel FA
    Lakartidningen; 1975 Oct; 72(43):4173. PubMed ID: 1177632
    [No Abstract]   [Full Text] [Related]  

  • 2. [Combination therapy of Parkinson's syndrome using L-dopa and a decarboxylase inhibitor].
    Fischer PA; Schneider E; Jacobi P; Maxion H
    Med Welt; 1973 Nov; 24(45):1742-6. PubMed ID: 4768206
    [No Abstract]   [Full Text] [Related]  

  • 3. [Parosmia and anosmia under L-dopa therapy (author's transl)].
    Neundörfer B; Valdivieso T
    Nervenarzt; 1977 May; 48(5):283-4. PubMed ID: 895952
    [No Abstract]   [Full Text] [Related]  

  • 4. Levodopa treatment of Parkinson's syndrome: past and future.
    Pletscher A
    Adv Neurol; 1990; 53():469-73. PubMed ID: 2239486
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of parkinsonism with l-dopa and a decarboxylase inhibitor. An electrophysiological and clinical study.
    Dietrichson P; Presthus J; Holmsen R
    Eur Neurol; 1975; 13(4):339-49. PubMed ID: 1149754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Trial use of L-dopa associated with a dopa-decarboxylase inhibitor in Parkinson's syndrome].
    Carotti A; Tomassetti G; Lucciarini L; Barone G; Mugnai A
    Clin Ter; 1974 Jul; 70(1):9-15. PubMed ID: 4153252
    [No Abstract]   [Full Text] [Related]  

  • 7. [Progress in therapy of Parkinsonian syndrome].
    Völler GW
    Hippokrates; 1975 Feb; 46(1):17-33. PubMed ID: 1091605
    [No Abstract]   [Full Text] [Related]  

  • 8. [Results after 3 to 5 years of treatment of 219 cases of Parkinson's syndrome treated by L-Dopa and an L-Dopa -decarboxylase inhibitor combination].
    Boudin G; Pepin B; Guillard A; Godlewski S; Fabiani JM; Haguenau M
    Rev Neurol (Paris); 1974; 130(7-8):273-84. PubMed ID: 4217929
    [No Abstract]   [Full Text] [Related]  

  • 9. [Changes of blood pressure, pulse and electrolytes following long-term treatment of Parkinsonism using Ro 8-0576 (L-Dopa and decarboxylase inhibitor)].
    Eisenlohr JJ; Gehlen W
    Nervenarzt; 1975 Mar; 46(3):128-35. PubMed ID: 805381
    [No Abstract]   [Full Text] [Related]  

  • 10. [Results of prolonged treatment of Parkinson's disease with the L-dopa-benserazide combination].
    Casacchia M; Barba C; Ruggieri S; Zamponi A; Agnoli A
    Riv Neurol; 1974; 44(5):303-30. PubMed ID: 4217465
    [No Abstract]   [Full Text] [Related]  

  • 11. Induction of aromatic-L-amino acid decarboxylase by decarboxylase inhibitors in idiopathic parkinsonism.
    Boomsma F; Meerwaldt JD; Man in 't Veld AJ; Hovestadt A; Schalekamp MA
    Ann Neurol; 1989 Jun; 25(6):624-8. PubMed ID: 2742363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Long-term study on the anti-rigidity effect of L-dopa and a decarboxylase inhibitor (ro 8-0576) (author's transl)].
    Eisenlohr JJ; Gehlen W
    MMW Munch Med Wochenschr; 1974 Jul; 116(28):1353-6. PubMed ID: 4212699
    [No Abstract]   [Full Text] [Related]  

  • 13. [Clinical experiences with Nacom in the treatment of Parkinsonism].
    Paal G
    Med Welt; 1978 Feb; 29(8):320-4. PubMed ID: 634126
    [No Abstract]   [Full Text] [Related]  

  • 14. [Our experience in the treatment of Parkinson's disease with L-dopa plus RO 4-4602 combination].
    Campanella G; Pennetta R
    Acta Neurol (Napoli); 1974; 29(3):252-63. PubMed ID: 4417098
    [No Abstract]   [Full Text] [Related]  

  • 15. Mortality of patients with Parkinson's disease treated with levodopa.
    Marttila RJ; Rinne UK; Siirtola T; Sonninen V
    J Neurol; 1977 Oct; 216(3):147-53. PubMed ID: 72132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dystonia induced by combined treatment with L-dopa and MK-801 in parkinsonian monkeys.
    Rupniak NM; Boyce S; Steventon MJ; Iversen SD; Marsden CD
    Ann Neurol; 1992 Jul; 32(1):103-5. PubMed ID: 1642462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Therapeutic association of L-dopa and an inhibitor of peripheral decarboxylase in Parkinsonism. Preliminary results].
    De Divitiis E; Cerillo A; Tata MR; Decina A
    Acta Neurol (Napoli); 1973; 28(2):208-12. PubMed ID: 4709076
    [No Abstract]   [Full Text] [Related]  

  • 18. [Dopa-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated hemiparkinsonian monkeys].
    Chen S
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1992 Feb; 25(1):50-2, 64. PubMed ID: 1591961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. "Long term evaluation of combined treatment of Parkinson disease with L-dopa, peripheral decarboxylase inhibitors and bromocreptine".
    Caraceni T; Giovannini P; Girotti F; Parati E; Pederzoli M; Scigliano G
    Ital J Neurol Sci; 1981 Dec; 2(4):337-42. PubMed ID: 7333824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical and biochemical considerations on depressive states occuring during parkinsonian syndrome treated by L-Dopa].
    Gisselmann A; Boudry C; Marin A; Ballivet J
    Encephale; 1976; 2(2):105-13. PubMed ID: 1278088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.